Prevalence of Hyperkalemia in Diabetic and Non-Diabetic Patients with Chronic Kidney Disease: A Nested Case-Control Study

被引:33
|
作者
Loutradis, Charalampos [1 ]
Tolika, Panagiota [2 ]
Skodra, Alexandra [2 ]
Avdelidou, Afroditi [2 ]
Sarafidis, Pantelis A. [1 ]
机构
[1] Aristotle Univ Thessaloniki, Hippokrat Hosp, Dept Nephrol, Konstantinoupoleos 49, GR-54642 Thessaloniki, Greece
[2] Gen Hosp Grevena, Hemodialysis Unit, Grevena, Greece
关键词
Hyperkalemia; Diabetes; Chronic kidney disease; Angiotensin-converting enzyme inhibitors; GLOMERULAR-FILTRATION-RATE; POTASSIUM; HYPERTENSION; PREDICTORS; MELLITUS; BLOCKADE;
D O I
10.1159/000442393
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background: Hyperkalemia is a potentially life-threatening disorder, usually complicating chronic kidney disease (CKD). Factors superimposed to reduced renal function are further elevating hyperkalemia risk, but their contribution is not fully elucidated. This study aimed to compare the prevalence of hyperkalemia in diabetic and non-diabetic patients with CKD. Methods: This is a nested case-control study of 180 type-2 diabetic and 180 non-diabetic patients with CKD followed in a Nephrology outpatient clinic, matched for gender, age and estimated glomerular filtration rate. Type-1 diabetes or end-stage renal disease patients were excluded. Prevalence of hyperkalemia was defined as potassium >5 mEq/l or use of sodium polystyrene sulfonate, and further by potassium >5, >= 5.2 and >= 5.5 mEq/1. It was calculated in both groups in whole and CKD stages separately. Univariate and multivariate logistic regression analysis were conducted to identify factors associated with hyperkalemia. Results: The prevalence of hyperkalemia was higher in diabetic CKD patients (27.2 vs. 20%, p = 0.107) and remained around 30% higher with all secondary definitions used, but never reached statistical significance. In Stage 2, no difference was noted (8.7 vs. 17.4%, p = 0.665); in Stage 3, it was significantly higher in diabetics (28.6 vs. 17.5%, p = 0.036); and in Stage 4, it was equally high in both groups (35.5 vs. 32.3%, p = 0.788). In multivariate analysis, Stage 4 CKD (OR 4.535, 95% CI 1.561-13.173), use of angiotensin-converting enzyme inhibitors (ACEls; OR 2.228, 95% CI 1.254-3.958) and smoking (OR 2.254, 95% CI 1.218-4.171) were independently associated with hyperkalemia. Conclusions: Diabetes mellitus was found to elevate the prevalence of hyperkalemia only in CKD Stage 3 patients (moderately impaired renal function). Advanced CKD at Stage 4 and ACEIs are major determinants of hyperkalemia occurrence. (C) 2015 S. Karger AG, Basel
引用
收藏
页码:351 / 360
页数:10
相关论文
共 50 条
  • [1] PREVALENCE OF HYPERKALEMIA IN MATCHED DIABETIC AND NON-DIABETIC PATIENTS WITH CHRONIC KIDNEY DISEASE: A NESTED CASE-CONTROL STUDY
    Loutradis, C.
    Tolika, P.
    Skodra, A.
    Avdelidou, A.
    Sarafidis, P.
    JOURNAL OF HYPERTENSION, 2016, 34 : E143 - E144
  • [2] Hospital admissions in diabetic and non-diabetic patients: A case-control study
    Tomlin, Andrew M.
    Tilyard, Murray W.
    Dovey, Susan M.
    Dawson, Alexander G.
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2006, 73 (03) : 260 - 267
  • [3] Measurement of pupillary diameter in diabetic and non-diabetic patients: a case-control study
    Mvogo, S. R. Ebana
    Dohvoma, V. A.
    Epee, E.
    Mvogo, C. Ebana
    JOURNAL FRANCAIS D OPHTALMOLOGIE, 2020, 43 (08): : 770 - 773
  • [4] Prevalence of miR146a Gene Polymorphisms in Diabetic and Non-diabetic Patients with Chronic Kidney Disease
    Sargazi, Sara
    Mollashahi, Behrouz
    Sargazi, Saman
    Heidari Nia, Milad
    Saravani, Ramin
    Mirinejad, Shekoufeh
    Alidadi, Ali
    IRANIAN JOURNAL OF SCIENCE AND TECHNOLOGY TRANSACTION A-SCIENCE, 2022, 46 (01): : 21 - 31
  • [5] Prevalence of miR146a Gene Polymorphisms in Diabetic and Non-diabetic Patients with Chronic Kidney Disease
    Sara Sargazi
    Behrouz Mollashahi
    Saman Sargazi
    Milad Heidari Nia
    Ramin Saravani
    Shekoufeh Mirinejad
    Ali Alidadi
    Iranian Journal of Science and Technology, Transactions A: Science, 2022, 46 : 21 - 31
  • [6] Endothelin antagonists for diabetic and non-diabetic chronic kidney disease
    Kohan, Donald E.
    Pollock, David M.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2013, 76 (04) : 573 - 579
  • [7] Prevalence of Bone Loss in Mandibular Future Abutment Teeth among Diabetic and Non-Diabetic Patients: A Retrospective Case-Control Study
    Madi, Marwa
    Bakhurji, Eman
    Alghwainem, Ali
    Alamer, Ali
    Alarfaj, Salma
    AlRatroot, Soha
    Pavlic, Verica
    OPEN DENTISTRY JOURNAL, 2022, 16
  • [8] Clonal Hematopoiesis of Indeterminate Potential and Diabetic Kidney Disease: A Nested Case-Control Study
    Denicolo, Sara
    Vogi, Verena
    Keller, Felix
    Thoni, Stefanie
    Eder, Susanne
    Heerspink, Hiddo J. L.
    Rosivall, Laszlo
    Wiecek, Andrzej
    Mark, Patrick B.
    Perco, Paul
    Leierer, Johannes
    Kronbichler, Andreas
    Steger, Marion
    Schwendinger, Simon
    Zschocke, Johannes
    Mayer, Gert
    Jukic, Emina
    KIDNEY INTERNATIONAL REPORTS, 2022, 7 (04): : 876 - 888
  • [9] USE OF ANTIHYPERTENSIVE MEDICATIONS IN DIABETIC AND NON-DIABETIC CHRONIC KIDNEY DISEASE AND HEMODIALYSIS PATIENTS: A DUE STUDY
    Kumar, P.
    Begum, A.
    Attur, R. P.
    VALUE IN HEALTH, 2016, 19 (07) : A516 - A516
  • [10] Endothelin receptor antagonists in diabetic and non-diabetic chronic kidney disease
    Ivkovic, Vanja
    Bruchfeld, Annette
    CLINICAL KIDNEY JOURNAL, 2024, 17 (04)